A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures
NCT04257604 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 243
Last updated 2020-02-06
Summary
The primary objective of the present study will be to assess the effectiveness of add-on perampanel in participants with focal seizures in a real-life clinical setting.
Conditions
- Partial Seizures
Interventions
- DRUG
-
Perampanel
Perampanel tablets.
Sponsors & Collaborators
-
Eisai Limited
lead INDUSTRY
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-01-03
- Primary Completion
- 2019-04-30
- Completion
- 2019-04-30
- FDA Drug
- Yes
More Related Trials
-
Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.
NCT02727101 ·Status: TERMINATED ·Phase: PHASE4
-
A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures
NCT01393743 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
NCT04015141 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Intravenous Perampanel in Japanese Participants With Epilepsy
NCT03754582 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
NCT03288129 ·Status: COMPLETED ·Phase: PHASE4
-
An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects
NCT02427607 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures
NCT04202159 ·Status: COMPLETED
-
Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization
NCT02726074 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Efficacy and Safety of Perampanel Monotherapy in the Treatment of Children With Focal Epilepsy
NCT05497193 ·Status: UNKNOWN
-
A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures
NCT01618695 ·Status: COMPLETED ·Phase: PHASE3
-
A Multi-center RWS of Perampanel as an add-on Treatment for Epileptic Seizures in Chinese Children
NCT05274035 ·Status: UNKNOWN
-
A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures
NCT05533814 ·Status: COMPLETED ·Phase: PHASE4
-
A China RWS to Evaluate the Effectiveness and Safety of Perampanel as an add-on Treatment for Epileptic Seizure
NCT05257915 ·Status: UNKNOWN
-
Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus
NCT05684978 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older
NCT03836924 ·Status: COMPLETED
-
A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents
NCT01161524 ·Status: COMPLETED ·Phase: PHASE2
-
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
NCT06453213 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs
NCT01527006 ·Status: COMPLETED ·Phase: PHASE2
-
A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years
NCT02033902 ·Status: COMPLETED
-
Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy
NCT02914314 ·Status: COMPLETED ·Phase: PHASE2
-
To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
NCT00699582 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
NCT00699972 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
NCT00735397 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
NCT02834793 ·Status: TERMINATED ·Phase: PHASE3
-
This is a Retrospective Study on the Use of CENOBAMATE as Adjunctive Treatment in Patients Suffering From Epilepsy in Early Access Program in Germany, France and UK
NCT05747001 ·Status: COMPLETED